Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8330662 | 0.85 | CYP1A2 (0.52) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL3737638 | 0.83 | CYP1A2 (0.60) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL8762158 | 0.83 | CYP1A2 (0.55) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL3192674 | 0.80 | TSHR (0.65) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL1993159 | 0.80 | CYP1A2 (0.52) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL29507015 | 0.80 | CYP1A2 (0.52) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL5594691 | 0.80 | GPR35 (0.50) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL22833410 | 0.80 | CYP1A2 (0.52) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL18589140 | 0.80 | ALDH1A1 (0.49) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 | |
| SCHEMBL9719281 | 0.79 | TDP1 (0.71) | CYP1A2TDP1TSHRSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024158872-A1 | 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-112321510-A | Preparation method of 4-bromo-5-methyl-1H-indazole | 无锡双启科技有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-104169277-B | Aurora kinase and flt3 kinase modulators | 赛勒姆公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20160009735-A1 | Glucokinase Activators | TAKEDA PHARMACEUTICAL (US) | 2016-01-14 | — | — | US | disclosed |
| EP-2812328-B1 | AURORA AND FLT3 KINASES MODULATORS | SAREUM LTD (GB) | 2015-11-18 | — | — | EP | disclosed |
| US-9139598-B2 | Glucokinase activators | TAKEDA CALIFORNIA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-1565452-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-05-05 | — | — | US | disclosed |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-03 | — | — | US | disclosed |
| US-6858637-B2 | Treating rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, and bronchial asthma; e.g., 2-Methoxynaphthalene-1-carboxylic acid benzyl-indan-2-yl-amide | NEUROGEN CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1487796-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-03-11 | — | — | US | disclosed |
| WO-2003082826-A1 | SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-4060626-A | Indole-carboxylic carbon compounds and pharmaceutical compositions containing them | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048913-A1 | Substituted biaryl amides as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | CYP1A2 996/4885TDP1 4028/4885TSHR 207/4885 |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CYP1A2 4560/4885TDP1 4534/4885TSHR 1755/4885 |
| US-20160009735-A1 | Glucokinase Activators | GCK, GCKR, GALK1 | CYP1A2 1638/4885TDP1 2843/4885TSHR 3402/4885 |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | CYP1A2 3693/4885TDP1 3878/4885TSHR 1741/4885 |
| US-20050096358-A1 | Substituted biaryl amides as C5A receptor modulators | C5AR1, C5AR2, C3AR1 | CYP1A2 975/4885TDP1 4185/4885TSHR 198/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | CYP1A2 735/4885TDP1 4048/4885TSHR 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.